Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Annovis Bio Inc
(NY:
ANVS
)
9.190
-0.420 (-4.37%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Annovis Bio Inc
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Annovis Bio Inc. (NYSE: ANVS) CEO Discusses Findings of Buntanetap Phase 2/3 Alzheimer’s Study on the Bell2Bell Podcast
August 20, 2024
Via
Investor Brand Network
ANVS Stock Earnings: Annovis Bio Beats EPS for Q2 2024
August 19, 2024
ANVS stock results show that Annovis Bio beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Announces Q2 2024 Financial Results, Provides Update Showing ‘Productive’ Recent Months
August 15, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Given $21.00 Price Target by EF Hutton
August 14, 2024
Via
Investor Brand Network
Studies Show Protein, Reelin, Protects Brain Against Alzheimer’s, Aging
August 14, 2024
Via
Investor Brand Network
Peering Into Annovis Bio's Recent Short Interest
July 03, 2024
Via
Benzinga
Why Did Annovis Bio (ANVS) Stock Close Up 80% Today?
July 02, 2024
ANVS stock closed up more than 75% today after Annovis announced encouraging clinical trial results for its Parkinson's drug, buntanetap.
Via
InvestorPlace
Annovis Bio Inc. (NYSE: ANVS) Lead Compound Shows Synergistic Cognitive Enhancement
August 14, 2024
Via
Investor Brand Network
Annovis Bio Inc. (NYSE: ANVS) Secures U.S. Patent Covering Methods For Treating TBI and Preventing Nerve Cell Death With Buntanetap
August 12, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment Model
August 08, 2024
Via
Investor Brand Network
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Release Promising Clinical Data As Global Alzheimer’s Disease Therapeutics Market Grows
August 07, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Reports on Clinical Data Showing Lead Compound Combined with GLP-1 Agonist Enhances Cognition
August 06, 2024
Via
Investor Brand Network
Alzheimer’s Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
August 06, 2024
EQNX::TICKER_START (NYSE:ANVS),(NYSE:MRK),(NASDAQ:SNY),(NYSE:JNJ),(NYSE:NVS) EQNX::TICKER_END
Via
FinancialNewsMedia
Lucrative Incentive for Biotechs as Global Alzheimer’s Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
August 06, 2024
EQNX::TICKER_START (NYSE:ANVS),(NYSE:PFE),(NYSE:LLY),(NYSE:GSK),(NYSE:NVO) EQNX::TICKER_END
Via
FinancialNewsMedia
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
August 06, 2024
From
FN Media Group LLC
Via
GlobeNewswire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) CEO Featured in Latest Bell2Bell Podcast, Recorded Live at AAIC 2024
August 05, 2024
Via
Investor Brand Network
Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
August 06, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Annovis Bio Inc. (NYSE: ANVS) Announces FDA Approval to Transition to New Form of Buntanetap for Future Clinical Trials
July 30, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Receives US Patent for Methods of Treating Acute Traumatic Brain Injury with Its Lead Drug Candidate
July 24, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Annovis Bio Inc. (NYSE: ANVS) Announces New Executive Team Members
July 23, 2024
Via
Investor Brand Network
Annovis Bio Inc. (NYSE: ANVS) Announces New Data From Phase III Study of Buntanetap for Early Parkinson’s Disease
July 19, 2024
Via
Investor Brand Network
Annovis Bio Inc. (NYSE: ANVS) Files New Composition of Matter Patent for Buntanetap
July 17, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Secures FDA Approval for New Form of Buntanetap
July 16, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Costco To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Thursday
July 11, 2024
Via
Benzinga
Why SeaStar Medical Holding Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
July 10, 2024
Via
Benzinga
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Names Four New Members to Executive Team
July 09, 2024
Via
Investor Brand Network
Why NIO Shares Are Trading Lower By Over 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session
July 05, 2024
Shares of NIO Inc. (NYSE:NIO) fell sharply during Friday's session after the company disclosed that Steven Wei Feng has resigned as the Chief Financial Officer for personal and family
Via
Benzinga
What's Going On With Annovis Shares Today?
July 03, 2024
Annovis Bio shares rise in premarket trading on positive Phase III Parkinson's study results for buntanetap, showing cognitive improvements and stability compared to placebo.
Via
Benzinga
Tesla, Paramount Global, Annovis Bio, Eli Lilly, Amazon: Why These 5 Stocks Are On Investors' Radars Today
July 02, 2024
On Tuesday, the Dow Jones Industrial Average rose by 0.4%, closing at $39,331.85, while the S&P 500 also ended the day in positive territory.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
What's Going With Annovis Bio Shares Tuesday?
July 02, 2024
Annovis announced new data from its Phase III Parkinson's study. The study showed improvements on the Unified Parkinson's Disease Rating Scale following treatment with Buntanetap.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.